ScreenPoint Medical, known as The Breast AI Company, has released results from the large-scale MASAI randomized controlled trial in Sweden, highlighting the impact of its Transpara Detection system on mammography screening. The study, which included over 105,000 women, found that AI-assisted screening led to a 12 percent reduction in interval cancers and a 27 percent decrease in aggressive non-luminal A cancers compared with traditional screening practices. MASAI is the first trial of its kind to evaluate whether artificial intelligence can improve breast cancer detection while reducing the workload for radiologists. Interval cancers are diagnosed between scheduled screening rounds or within two years of the last screening and tend to carry higher mortality compared with cancers detected during routine screening. Previous research from 2023 and 2025 published in The Lancet Oncology and The Lancet Digital Health showed that Transpara Detection increased the cancer detection rate by 29 percent while lowering the reading workload by 44 percent compared with standard double reading.
Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India
Pieter Kroese, Chief Executive Officer of ScreenPoint Medical, said that the MASAI trial marks a major milestone for breast AI. He emphasized that the technology is now shaping large-scale healthcare delivery, helping providers work more efficiently, and most importantly, improving outcomes for women globally. He added that with this level of evidence, the focus should shift from debating the use of AI to ensuring that women everywhere benefit from it.
Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk
Key results from the trial include reductions in invasive cancers by 16 percent, large tumors by 21 percent, and non-luminal A interval cancers by 27 percent in the intervention group compared with controls. Overall, the MASAI trial demonstrated a 29 percent increase in cancer detection and a non-inferior 12 percent reduction in interval cancer rates without increasing false positives, showing higher sensitivity and maintained specificity. Sensitivity was 80.5 percent in the AI-assisted group compared with 73.8 percent in the control group, with consistent outcomes across different age groups and breast densities.
Transpara Breast AI has been adopted by many leading healthcare programs worldwide, providing radiologists with a second set of eyes to detect cancers earlier and reduce reading workload for both 2D and 3D mammography. Supported by more than 55 peer-reviewed publications, Transpara has been proven to help radiologists detect more cancers sooner while addressing challenges such as breast density, patient ethnicity, and varying levels of radiologist experience.
Dr. Kristina Lång, lead researcher at Lund University, stated that the findings show AI-supported mammography screening can help identify significant breast cancers earlier and reduce the occurrence of interval cancers, particularly aggressive tumors. Early detection of these cancers may improve outcomes and make a meaningful difference in women’s health worldwide.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
